For many people with Crohn’s disease, reaching remission—when inflammation is no longer detectable—seems like a major victory ...

15, 2024 — Scientists uncovered an overlooked mechanism in the gut immune system of patients suffering from severe cases of Crohn's disease. The discovery may help define how to treat patients ...

Lutikizumab is under clinical development by AbbVie and currently in Phase II for Crohn's Disease (Regional Enteritis).

Vedolizumab prevented the postoperative recurrence of Crohn’s disease and should be considered a prophylactic treatment in ...

Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s ...

The resulting paper, "Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: Post-hoc analysis of the RISK study," appeared in Gut.

The resulting paper, "Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: Post-hoc analysis of the RISK study," appears in Gut.

Large numbers of Australians are turning to surgery to screen for gastrointestinal diseases, as a major health insurer ...

Zinpentraxin alfa is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Crohn's Disease (Regional Enteritis).